Table Of Content

Journal of Internal Medicine 2004; 255: Author index Adlercreutz, H. see von Hertzen, L. 3olinder, J. see SchGlin, A. Agardh, E.E., Carlsson, S., Ahlbom, A., Efendic, S., Grill, V.. 30onen, S., Haentjens, P., Vandenput, L. & Vanderschueren, D. Hammar, N., Hilding, A. & Ostenson, C.-G. Coffee consump- Preventing osteoporotic fractures with antiresorptive ther- tion, type 2 diabetes and impaired glucose tolerance in apy: implications of microarchitectural changes, 1 Swedish men and women, 645 Borg, H. see Scholin, A. Agewall, S. see Rohani, M. Botta, F. see Giannini, E. Agozzino, F., Picca, M. & Pelosi, G. Association of microalbumi Brismar, K. see Kistner, A. nuria and left ventricular hypertrophy, 424 Brune, K. see Dormann, H. Ahlbom, A. see Agardh, E.E. Ahrén, B. see Lindeberg, S. Cakir, B., Heiss, G., Pankow, J.S., Salomaa, V., Sharrett, A.R., Airaksinen, K.E.J. see Luukinen, H. Couper, D. & Weston, B.W. Association of the Lewis genotype Ajello, P. see D'Auria, F. with cardiovascular risk factors and subclinical carotid Alessi, M.-C. see Mavri, A. atherosclerosis: the Atherosclerosis Risk in Communities Al-Khalili, F. see Janszky, I. (ARIC) study, 40 Aman, J. see Ingberg, C.-M. Calandra, S. seé Valdivielso, P. Andersson, S. see Wisten, A. Capelli, A. see Incalzi, R.A. Andersson, U. & Erlandsson-Harris, H. HMGB1 is a potent trigger Carlsson, S. see Agardh, E.E. of arthritis, 344 Carmeliet, P. Manipulating angiogenesis in medicine, 538 Andersson, U.G. & Tracey, K.J. HMGB1, a pro-inflammatory Castro Cabezas, M. see Halkes, C.J.M. cytokine of clinical interest: introduction, 318 Celsi, G. see Kistner, A. Andrés, E. & Dimarcg, J.L. Cationic antimicrobial peptides: update Chan, M.H.M., Wong, V.W.S., Wong, C.K., Chan, P.K.S., Chu, of clinical development, 519 C.M., Hui, D.S.C., Suen, M.W.M., Sung, J.J.Y., Chung, S.S.C. Andrés, E., Noel, E., Schlienger, J.L. & Blicklé, J.F. Mild cobalamin & Lam, C.W.K. Serum LD1 isoenzyme and blood lymphocyte deficiency associated with long-term metformin intake subsets as prognostic indicators for severe acute respiratory reply, 302 syndrome, 512 Arena, V. see Incalzi, R.A. Chan, P.K.S. see Chan, M.H.M. Arner, P. see Dahlman, I. Chaves, F.J. see Giner, V Arnesen, H. see Hjerkinn, E.M Cheng, T.O. Waist circumference versus body mass index in risk Arnqvist, H. see Scholin, A. prediction of coronary heart disease: comparing apples and Arvidsson, B. see Ingberg, C.-M. oranges, 690 Arvidsson, E., Blomqvist, L. & Rydén, M. Depot-specific differences Chiarbonello, B. see Giannini, E. in perilipin mRNA but not protein expression in obesity, 595 Chisari, C. see Cupisti, A. Asplund, K. see Glader, E.-L. Chu, C.M. see Chan, M.H.M. Asplund, K. see Rodu, B. Chung, S.S.C. see Chan, M.H.M. Axdorph, U. see Landgren, O. Cole, P. see Rodu, B. Axelsen, M. see Johanson, E.H. Cordain, L. see Lindeberg, S. Axelsson, C. see Svensson, L. Cornu, G. see Dejardin, A Azaz-Livshits, T. see Dormann, H. Couper, D. see Cakir, B. Criegee-Rieck, M. see Dormann, H. Baldissera, E. see D'Auria, F. Cupisti, A., Licitra, R., Chisari, C., Stampacchia, G., D'Alessandro, Barsotti, G. see Cupisti, A. C., Galetta, F., Rossi, B. & Barsotti, G. Skeletal muscle and Beevers, D.G. see Spencer, C.G.C. nutritional assessment in chronic renal failure patients on a Bek, T. see Knudsen, S.T. protein-restricted diet, 115 3erg, G. see Milakovic, M. Cupisti, A. see Franzoni, F. 3erglund, G. see Janzon, E. 3erglund, G. see Nilsson, P.M. Dahlman, I., Wahrenberg, H., Persson, L. & Arner, P. No Berne, C. see Ingberg, C.-M. association of reported functional protein tyrosine phospha- Bianchi, M.E. see Miiller, S. tase 1B 3’ UTR gene polymorphism with features of the Bingham, S. see Yuyun, M.P. metabolic syndrome in a Swedish population, 694 Bisoendial, R.J. see Hovingh, G.K. D'Alessandro, C. see Cupisti, A. Bjork, E. see SchGlin, A. van Dam, M. see Hovingh, G.K. 3j6rkholm, M. see Landgren, O. D'Auria, F., Rovere-Querini, P., Giazzon, M., Ajello, P., Baldissera, Bjorklund, L. see Schdlin, A. E., Manfredi, A.A. & Sabbadini, M.G. Accumulation of plasma Blann, A.D. see Spencer, C.G.C. nucleosomes upon treatment with anti-tumour necrosis Bleeker-Rovers, C.P., Jager, G., Tack, C.J., van der Meer, J.W.M. & factor-x antibodies, 409 Oyen, W.J.G. F-18-fluorodeoxyglucose positron emission Day, N.E. see Yuyun, M.P. tomography leading to a diagnosis of septic thrombophlebitis Dejardin, A., Goffette, P., Moulin, P., Verhelst, R., Cornu, G., De of the portal vein: description of a case history and review of Plaen, J.P. & Persu, A. Severe hypoplasia of the abdominal the literature, 419 aorta and its branches in a patient and his daughter, 130 Blickleé, J.F. see Andres, E. Dellborg, M. see Gunnarsson, G. Blohmé, G. see Schélin, A. DeMets, D.L. Statistical issues in interpreting clinical trials, 529 Blomavist, L. see Arvidsson, E. De Plaen, J.F. see Dejardin, A. Boissel, J.-P. Planning of clinical trials, 427 Dimarcgq, J.L. see Andrés, E. © 2004 Blackwell Publishing Ltd AUTHOR INDEX Dormann, H., Neubert, A., Criegee-Rieck, M., Egger, T., Radespiel- Goffette, P. see Dejardin, A. lréger, M., Azaz-Livshits, T., Levy, M., Brune, K. & Hahn, Gonzalez, P. see Valdivielso, P. E.G. Readmissions and adverse drug reactions in internal Graf, J. see Kriiger, S. medicine: the economic impact, 653 Grill, V. see Agardh, E.E. Dotevall, A. see Rosengren, A. Grimfors, G. see Landgren, O. Dullaart, R.P.F., Hoogenberg, K., Rouwé, C.W. & Stulp, B.K. Groen, A.K. see Hovingh, G.K. Family with autosomal dominant hyperinsulinism associated Gronbeek, M. see Nielsen, N.R. with A456V mutation in the glucokinase gene, 143 Groop, P.-H. see von Hertzen, L. Dunder, K.. Lind, L., Zethelius, B. & Lithell, H. A new Q/QS pattern Grove, E.L., Orntoft, T.F., Lassen, J.F.. Jensen, H.K. & Kristensen, on the resting electrocardiogram is associated with impaired S.D. The platelet polymorphism PI“? is a genetic risk factor insulin secretion and a poor prognosis in elderly men for myocardial infarction, 637 independently of history of myocardial infarction, 221 Gudbjérnsdottir, S. see Schodlin, A. Duran, J.C. see Valdivielso, P Gunnarsson, G., Eriksson, P. & Dellborg, M. Continuous ST- segment monitoring of patients with left bundle branch block Efendic, S. see Agardh, E.I and suspicion of acute myocardial infarction, 571 Egger, T. see Dormann, H Gurney, D. see Spencer, C.G.C. ggertsen, G. see Harper, P. Gustafson, B. see Johanson, E.H. Eggertsen, R. see Milakovic, M. Gustavsson, A. see Landgren, O Engstrém, G. see Janzon, | Ericson, M. see Janszky, | Haentjens, P.) see Boonen, S. Eriksson, J.W. see Schélin, A Hahn, E.G. see Dormann, H. Eriksson, M., Wallander, M.-A., Krakau, I., Wedel, H. & Halkes, C.J.M., van Wijk, J.P.H., Ribalta, J.. Masana, L. & Castro Svardsudd, K. Birth weight and cardiovascular risk factors in Cabezas, M. Diurnal triglyceridaemia and insulin resistance a cohort followed until 80 years of age: the study of men born in mildly obese subjects with normal fasting plasma lipids, 74 in 1913, 236 Hallert, C. see Lofgren, U.-B. Eriksson, P. see Gunnarsson, G. Hammar, N. see Agardh, E.E. Erkelens. D.W. see Stades, A.M.E. Hanrath, P. see Kriiger, S. Erlandsson-Harris, H. see Andersson, U. Hansson, L.-O. see Saleh, N. Harper, P., Floderus, Y., Holmstrém, P., Eggertsen, G. & Gafvels, Felmeden, D.C. see Spencer, C.G.C M. Enrichment of HFE mutations in Swedish patients with Femia, F.R. see Franzoni, | familial and sporadic form of porphyria cutanea tarda, 684 Hasselblom, S., Linde, A. & Ridell, B. Hodgkin’s lymphoma, Ferrer-Barriendos, J. see Sambrook, P.N. Filzmaier, K. see Kriiger, S. Epstein-Barr virus reactivation and fatal haemophagocytic Floderus, Y. see Harper, P. syndrome, 289 Forsberg, H. see Wisten, A. Hauser, A.C., Lorenz, M. & Sunder-Plassmann, G. The expanding Forsblom, C. see von Hertzen, L. clinical spectrum of Anderson—Fabry disease: a challenge to Franzoni, F., Galetta, F., Cupisti, A., Femia, F.R., Pentimone, F. & diagnosis in the novel era of enzyme replacement therapy, Santoro, G. Ultrasonic backscatter of the carotid wall in 629 young and older athletes, 52 Hayden, M.R. see Hovingh, G.K. Fumagalli, A. see Giannini, E. Hedblad, B. see Janzon, E. Furu, K. see Tonstad, S. Heickendorff, L. see Kanstrup, H. Heikens, J.T. see Stades, A.M.E. Heiss. G. see Cakir, B. Gafvels, M. see Harper, P. Herlitz, J. see Svensson, L. Gaines, K. see Sambrook, P.N Herrera, E. see Valdivielso, P. Galetta, F. see Cupisti, A. von Hertzen, L., Forsblom, C., Stumpf, K., Pettersson-Fernholm, Galetta, F. see Franzoni., F. K., Adlercreutz, H. & Groop, P.-H. on behalf of the finndiane Gambassi. G. see Incalzi, R.A. study group, Highly elevated serum phyto-oestrogen Garuti, R. see Valdivielso, P. concentrations in patients with diabetic nephropathy, 602 Gasbarrini, A. see Ojetti, V. Hilding, A. see Agardh, E.E. Gasbarrini, G. see Ojetti, V. Hjerkinn, E.M., Sandvik, L., Hjermann, I. & Arnesen, H. Effect of Gebre-Medhin, M. see Milakovic, M. diet intervention on long-term mortality in healthy middle- Geusens, P. see Sambrook, P.N. aged men with combined hyperlipidaemia, 68 Giannini, E., Risso, D., Botta, F.. Romagnoli, P., Malfatti, F., Hjermann, I. see Hjerkinn, E.M. Fumagalli, A., Testa, E., Podesta, E., Chiarbonello, B.., Hoekstra, J.B.L. see Stades, A.M.E. Polegato, S. & Testa, R. Prognosis of hepatocellular carcino- Hoffmann, R. see Kriiger, S. ma in anti-HCV positive cirrhotic patients: a single-centre Holleman, F. see Stades, A.M.E. comparison amongst four different staging systems, 399 Holmstrém, P. see Harper, P. Giazzon, M. see D'Auria, F. Hdlzl, B. see Strohmer, B. Giner, V., Tormos, C., Chaves, F.J., Saez, G. & Redon, J. Hoogenberg, K. see Dullaart, R.P.P. Microalbuminuria and oxidative stress in essential hyper- Hove, M.N. see Knudsen, S.T. tension, 588 Hovingh, G.K., Kuivenhoven, J.A., Bisoendial, R.J., Groen, A.K., Glader, E.-L., Stegmayr, B., Norrving, B., Terént, A., Hulter- van Dam, M., van Tol, A., Wellington, C., Hayden, M.R., Asberg. K., Wester, P.-O. & Asplund, K. for the Riks-Stroke Smelt, A.H.M. & Kastelein, J.J.P. HDL deficiency and Collaboration, Large variations in the use of oral antic- atherosclerosis: lessons from Tangier disease, 299 oagulants in stroke patients with atrial fibrillation: a Swedish Hui, D.S.C. see Chan, M.H.M. national perspective, 22 Hulter-Asberg, K. see Glader, E.-L. Gleim, G.W. & Tressler, C.S. Effects of losartan on diabetic Hutri-KahGnen, N. see Juonala, M. maculopathy in type 2 diabetic patients, 304 © 2004 Blackwell Publishing Ltd Journal of Internal Medicine 255: 7 AUTHOR INDEX Huttunen, H.J. & Rauvala, H. Amphoterin as an extracellular Kriiger, S., Filazmaier, K., Graf, J., Kunz, D., Stickel, T., Hoffmann, regulator of cell motility: from discovery to disease, 351 R., Hanrath, P. & Janssens, U. QRS prolongation on surface ECG and brain natriuretic peptide as indicators of left Incalzi, R.A., Arena, V., Capelli, A. & Gambassi, G. Isolated ventricular systolic dysfunction, 206 PACNS-like presentation ofa systemic vasculitis complicating Kuivenhoven, J.A. see Hovingh, G.K. a myelodysplastic syndrome, 674 Kunz, D. see Kriiger, S. Ingberg, C.-M., Palmér, M., Aman, J., Arvidsson, B., Schvarcz, E. & Berne, C. Body composition and bone mineral density in Labouriau, R. see Niemann, T. long-standing type | diabetes, 392 Laippala, P. see Luukinen, H. Izhevsky, D., Maple, J.T. & Ommen, S.R. Acute myocardial Lam, C.W.K. see Chan, M.H.M. infarction: an unusual culmination of rheumatic pancarditis Landgren, O., Bjérkholm, M., Konradsen, H.B., S6derqvist, M.. and antiphospholipid antibody syndrome, 296 Nilsson, B., Gustavsson, A., Axdorph, U., Kalin, M. & Grimfors, G. A prospective study on antibody response to Jacobson, S.H. see Kistner, A. repeated vaccinations with pneumococcal capsular polysac- Jager, G. see Bleeker-Rovers, C.P. charide in splenectomized individuals with special reference Janssens, U. see Kriiger, S. to Hodgkin's lymphoma, 664 Jansson, P.-A. see Johanson, E.H. Larsen, M.L. see Kanstrup, H. Janszky, I., Ericson, M., Mittleman, M.A., Wamala, S., Al-Khalili, Lassen, J.F. see Grove, E.L F., Schenck-Gustafsson, K. & Orth-Gomer, K. Heart rate Lassen, J.F. see Kanstrup, H. variability in long-term risk assessment in middle-aged Lauritzen, T. see Kanstrup, H. women with coronary heart disease: The Stockholm Female Lazar, M.A. see Steppan, C.M. Coronary Risk Study, 13 Levy, M. see Dormann, H. Janzon, E., Hedblad, B., Berglund, G. & Engstrém, G. Changes in Licitra, R. see Cupisti, A blood pressure and body weight following smoking cessation Lind, L. see Dunder, K. in women, 266 Lind, L. see Olsson, T. Jensen, G. see Nielsen, N.R. Linde, A. see Hasselblom, S. Jensen, H.K. see Grove, E.L. Lindeberg, S., Cordain, L., Rastam, L. & Ahrén, B. Serum uric acid Johanson, E.H., Jansson, P.-A., Gustafson, B., L6nn, L., Smith, U., in traditional Pacific Islanders and in Swedes, 373 Taskinen, M.-R. & Axelsen, M. Early alterations in the Lindgren, P., Jonsson, B. & Yusuf, S. Cost-effectiveness of postprandial VLDL1 apoB-100 and apoB-48 metabolism in clopidogrel in acute coronary syndromes in Sweden: a long- men with strong heredity for type 2 diabetes, 273 term model based on the cure trial, 562 Johansson, S. see Rosengren, A. Lindstedt, G. see Milakovic, M. Jokinen, E. see Juonala, M. Lindstrém, T. see Lofgren, U.-B Jonsson, B. see Lindgren, P. Lip, G.Y.H. see Spencer, C.G.C. Juhan-Vague, I. see Mavri, A. Lithell, H. see Dunder, K. Julian, D.G. Translation of clinical trials into clinical practice, 309 Lofgren, U.-B., Rosenqvist. U., Lindstrém, T., Hallert, C. & Jungner, I. see Walldius, G. Nystrom, F.H. Diabetes control in Swedish community Juonala, M., Viikari, J.S.A., Hutri-Kaéh6nen, N., Pietikadinen, M., dwelling elderly: more often tight than poor, 96 Jokinen, E., Taittonen, L., Marniemi, J., R6nnemaa, T. & Lonn, L. see Johanson, E.H. Raitakari, O.T. The 21-year follow-up of the Cardiovascular Lorenz, M. see Hauser, A.C. Risk in Young Finns Study: risk factor levels, secular trends Luben, R. see Yuyun, M.F. and east-west difference, 457 Luukinen, H., Koski. K., Laippala, P. & Airaksinen, K.E.]J. Orthostatic hypotension and the risk of myocardial infarction in the home-dwelling elderly, 486 Kalin, M. see Landgren, O. Kanstrup, H., Lassen, J.F., Heickendorff, L., Lauritzen, T. & Larsen, M.L. Quality of lipid-lowering therapy in patients with Mabuchi, H. see Yagi, K. ischaemic heart disease: a register-based study in 3477 Machin, D. On the evolution of statistical methods as applied to patients, 367 clinical trials, 521 Karlsson, A.F. see Sch6lin, A. Makita, N. see Takehara, N. Kastelein, J.J.P. see Hovingh, G.K. Malfatti, F. see Giannini, E. Kawabe, J. see Takehara, N. Manfredi, A.A. see D'Auria, F. Kawamura, Y. see Takehara, N. Manios, E. see Vemmos, K.N. Khaw. K.-T. see Yuyun, M.P. Maple, J.T. see Izhevsky, D. Kikuchi, K. see Takehara, N. Marniemi, J. see Juonala, M. Kistner, A., Jacobson, S.H., Celsi, G., Vanpee, M. & Brismar, K. Masana, L. see Halkes, C.J.M. IGFBP-1 levels in adult women born small for gestational age Mathai, D. see Varghese, G.M. suggest insulin resistance in spite of normal BMI, 82 Mavri, A., Alessi, M.-C. & Juhan-Vague, I. Hypofibrinolysis in the Kitabatake, A. see Takehara, N. insulin resistance syndrome: implication in cardiovascular Knudsen, S.T., Bek, T., Poulsen, P.L., Hove, M.N., Rehling, M. & diseases, 448 Mogensen, C.E. Effects of losartan on diabetic maculopathy in Mavrikakis, M. see Vemmos, K.N. type 2 diabetic patients — reply, 306 van der Meer, J.W.M. see Bleeker-Rovers, C.P. Kobayashi, J. see Yagi, K. Melton, M.E. see Sambrook, P.N. Konradsen, H.B. see Landgren, O. Meriini, G. & Westermark, P. The systemic amyloidoses: clearer Konstantopoulou, P. see Vemmos, K.N. understanding of the molecular mechanisms offers hope for Koski, K. see Luukinen, H. more effective therapies, 159 Krakau, I. see Eriksson, M. Messner, T. see Wisten, A. Krantz, P. see Wisten, A. Migneco, A. see Ojetti, V. Kristensen, S.D. see Grove, E. © 2004 Blackwell Publishing Ltd Journal of Internal Medicine 255: 7 AUTHOR INDEX Milakovic, M.,. Berg, G., Nystrém, E., Lindstedt, G., Gebre-Medhin, Radespiel-Tréger, M. see Dormann, H. M. & Eggertsen, R. Urinary iodine and thyroid volume in a Raitakari, O.T. see Juonala, M. Swedish population, 610 Rastam, L. see Lindeberg, S. Mittleman, M.A. see Janszky, I. Rauvala, H. see Huttunen, H.]. Mogensen, C.E. see Knudsen, S.T. Redon, J. see Giner, V. Mosekilde, L. see Vestergaard, P. Reginster, J.-Y. Prevention of postmenopausal osteoporosis with Moulin, P. see Dejardin, A. pharmacological therapy: practice and possibilities, 615 Miiller, S.. Ronfani, L. & Bianchi, M.E. Regulated expression and Rehling, M. see Knudsen, S.T. subcellular localization of HMGB1, a chromatin protein with Reiter, R. see Strohmer, B. a cytokine function, 332 Ribalta, J. see Halkes, C.J.M. Ribot, C. see Sambrook, P.N. Nasic, S. see Rodu, B. Ridell, B. see Hasselblom, S. Neubert, A. see Dormann, H. Risso, D. see Giannini, E. Rodu, B., Stegmayr. B., Nasic, S., Cole, P. & Asplund, K. The Nielsen, N.R., Schnohr, P., Jensen, G. & Gronbeek, M. Is the relationship between type of alcohol and mortality influenced influence of smoking and smokeless tobacco use on weight by socio-economic status?, 280 amongst men, 102 Niemann, T., Labouriau, R., Sorensen, H.T., Thorsgaard. N. & Rohani, M. & Agewall, S. Oral snuff impairs endothelial function Nielsen, T.T. Prognostic impact of different regional referral in healthy snuff users, 379 practices for interventional investigation and coronary Romagnoli, P. see Giannini, E. treatment after exercise testing: a population-based 5-year Ronfani, L. see Miiller, S. follow-up study, 478 ROnnemaa, T. see Juonala, M. Nilsson, B. see Landgren, O. Rosengren, A., Dotevall, A., Wilhelmsen, L., Thelle, D. & Nilsson, J.-A. see Nilsson, P.M Johansson, S. Coffee and incidence of diabetes in Swedish Nilsson, P.M., Nilsson, J.-A. & Berglund, G. Family burden of women: a prospective 18-year follow-up study, 89 cardiovascular mortality: risk implications for offspring in a Rosenqvist, U. see Lofgren, U.-B. national register linkage study based upon the Malmé Rossi, B. see Cupisti, A. Rosvold, E.O. see Tonstad, S. Preventive Project, 229 Rouwe, C.W. see Dullaart, R.P.P. Nilsson, T. see Saleh, N. Nista, E.C. see Ojetti, V. Rovere-Querini, P. see D'Auria, F. Noel, E. see Andres, E. Rydén, M. see Arvidsson, E. Nordlander, R. see Svensson, L. Norrving, B. see Glader, E.-L. Sabbadini, M.G. see D'Auria, F. Nystrom, E. see Milakovic, M. Saez, G. see Giner, V. ystrom, F.H. see Lofgren, U.-B Saleh, N., Svane, B., Velander, M., Nilsson, T., Hansson, L.-O. & Nystrom, L. see Schélin, A. lornvall, P. C-reactive protein and myocardial infarction during percutaneous coronary intervention, 33 Ojetti, V.. Migneco, A., Zocco, M.A., Nista, E.C., Gasbarrini, G. & Salomaa, V. see Cakir, B. Gasbarrini, A. Beta-lactamase inhibitor enhances Helicobacter Sambrook, P.N., Geusens, P., Ribot, C., Solimano, J.A., Ferrer- pylori eradication rate, 125 Barriendos, J., Gaines, K., Verbruggen, N. & Melton, M.E. Olsson, T., Terent, A. & Lind, L. Rapid Emergency Medicine score: Alendronate produces greater effects than raloxifene on bone a new prognostic tool for in-hospital mortality in nonsurgical density and bone turnover in postmenopausal women with emergency department patients, 579 low bone density: results of EFFECT (EFficacy of FOSAMAX Ommen, S.R. see Izhevsky, D. versus EVISTA~ Comparison Trial) International, 503 Orntolt, T.F. see Grove, E.L. Sandvik, L. see Hjerkinn, E.M. Orth-Gomer, K. see Janszky, I. Santoro, G. see Franzoni, F. Ostenson, C.-G. see Agardh, E.} Sato, N. see Takehara, N. Ostman, J. see Schélin, A Schenck-Gustafsson, K. see Janszky, I. Oyen, W.J.G. see Bleeker-Rovers, C.P. Schlienger, J.L. see Andrés, E. Schnohr, P. see Nielsen, N.R. Schélin, A., Bjérklund, L., Borg, H., Arnqvist, H., Bjork, E., Palmér, M. see Ingberg Blohmeé, G., Bolinder, J., Eriksson, J.W., Gudbjérnsdottir, S.., Pankow, J.S. see Cakir, Nystrom, L., Ostman, J., Karlsson, A.F. & Sundkvist, G. Islet Paulweber, B. see Strohmer, B. antibodies and remaining B-cell function 8 years after Pedrinelli, R. Association of microalbuminuria and left ventricular diagnosis of diabetes in young adults: a prospective follow-up hypertrophy — reply, 426 of the nationwide Diabetes Incidence Study in Sweden, 384 Pelosi, G. see Agozzino, F. Schvarcez, E. see Ingberg, C.-M. Pentimone, F. see Franzoni, F Sharrett, A.R. see Cakir, B. Persson, L. see Dahlman, I. Shenoy, M. see Varghese, G.M. Persu, A. see Dejardin, A. Shiobara, S. see Yagi, K. Peter, S. see Varghese, G.M. Skurtveit, S. see Tonstad, S. Pettersson-Fernholm, K. see von Hertzen, L. Sleight. P. Where are clinical trials going? Society and clinical Picca, M. see Agozzino., F. trials, 151 Pietikainen, M. see Juonala, M. Smelt, A.H.M. see Hovingh, G.K. Podesta, E. see Giannini, E. Smith, U. see Johanson, E.H. Polegato, S. see Giannini, E. Séderqvist, M. see Landgren, O Poulsen, P.L. see Knudsen, S.T. Solimano, J.A. see Sambrook, P.N. 2004 Blackwell Publishing Ltd Journal of Internal Medicine 255: 2p7 as 35 AUTHOR INDEX Sorensen, H.T. see Niemann, T. Vanderschueren, D. see Boonen, S. Spencer, C.G.C., Gurney, D., Felmeden, D.C., Blann, A.D., Beevers, Vanpee, M. see Kistner, A. D.G. & Lip, G.Y.H. Platelet and haemorheological markers in Varghese, G.M., Shenoy, M., Subramanian, S., Peter, S$. & Mathai, ‘high risk’ hypertensives are improved by tighter blood D. Colonic malignancy with recurrent bacteraemia present- pressure control and cardiovascular risk management: a ing as pyrexia of unknown origin, 692 substudy of the Anglo-Scandinavian Cardiac Outcomes Trial Velander, M. see Saleh, N. (ASCOT), 59 Vemmos, K.N., Tsivgoulis, G., Spengos, K., Zakopoulos, N., Spengos, K. see Vemmos, K.N. Synetos, A., Manios, E., Konstantopoulou, P. & Mavrikakis, Stades, A.M.E., Heikens, J.T., Erkelens, D.W., Holleman, F. & M. U-shaped relationship between mortality and admission Hoekstra, J.B.L. Metformin and lactic acidosis: cause or blood pressure in patients with acute stroke, 257 coincidence? A review of case reports, 179 Verbruggen, N. see Sambrook, P.N. Stampacchia, G. see Cupisti, A. Verhelst, R. see Dejardin, A Stegmayr, B. see Glader, E.-L. Vestergaard, P. & Mosekilde, L. Parathyroid surgery is associated Stegmayr, B. see Rodu, B. with a decreased risk of hip and upper arm fractures in Steppan, C.M. & Lazar, M.A. The current biology of resistin 439 primary hyperparathyroidism: a controlled cohort study, 108 Stickel, T. see Kriiger, S. Viikari, J.S.A. see Juonala, M. Strohmer, B., Reiter, R., H6lzl, B. & Paulweber, B. Lack of association of the Gly972Arg mutation of the insulin Wahrenberg, H. see Dahlman, I. receptor substrate-1 gene with coronary artery disease in the Wallander, M.-A. see Eriksson, M. Austrian population, 146 Walldius, G. & Jungner, I. \polipoprotein B and apolipoprotein A- Stulp, B.K. see Dullaart, R.P.P. I: risk indicators of coronary heart disease and targets for Stumpf, K. see von Hertzen, L. lipid-modifying therapy, 188 Subramanian, S. see Varghese, G.M. Wamala, S. see Janszky, I. Suen, M.W.M. see Chan, M.H.M. Wang, H., Yang, H. & Tracey, K.J. Extracellular role of HMGB1 in Sunder-Plassmann, G. see Hauser, A.C. inflammation and sepsis, 320 Sundkvist, G. see Sch6lin, A. Wareham, N.J. see Yuyun, M.F. Sung, J.J.Y. see Chan, M.H.M. Wedel, H. see Eriksson, M. Svane, B. see Saleh, N. Welch, A. see Yuyun, M.F. Svardsudd, K. see Eriksson, M. Wellington, C. see Hovingh, G.K. Svensson, L., Axelsson, C., Nordlander, R. & Herlitz, J. Prognostic Wester, P.-O. see Glader, E.-L. value of biochemical markers, 12-lead ECG and patient Westermark, P. see Merlini, G. characteristics amongst patients calling for an ambulance Weston, B.W. see Cakir, B due to a suspected acute coronary syndrome, 469 van Wijk, J.P.H. see Halkes, C.J.M. Synetos, A. see Vemmos, K.N. Wilhelmsen, L. see Rosengren, A. Wisten, A., Andersson, S., Forsberg, H., Krantz, P. & Messner, T. Tack, C.J. see Bleeker-Rovers, C.P. Sudden cardiac death in the young in Sweden: electro- laittonen, L. see Juonala, M. cardiogram in relation to forensic diagnosis, 213 Takehara, N., Makita, N., Kawabe, J., Sato, N., Kawamura, Y., Wong, C.K. see Chan, M.H.M. Kitabatake, A. & Kikuchi, K. A cardiac sodium channel Wong, V.W.S. see Chan, M.H.M. mutation identified in Brugada syndrome associated with atrial standstill, 137 Yagi, K., Kobayashi, J., Yasue, S.. Yamaguchi, M., Shiobara, S. & Taskinen, M.-R. see Johanson, E.H. Mabuchi, H. Four unrelated cases with Takayasu arteritis Terént, A. see Glader, E.-L. and CD36 deliciency: possible link between these disorders, Terent, A. see Olsson, T. 6858 Testa, E. see Giannini, E. Yamaguchi, M. see Yagi, K. Testa, R. see Giannini, E. Yang, H. see Wang, H. Thelle, D. see Rosengren, A. Yasue, S. see Yagi, K. Thorsgaard, N. see Niemann, T. Yusuf, S. see Lindgren, P. Toftegaard Nielsen, T. see Niemann, T. Yuyun, M.F., Khaw, K.-T., Luben, R.. Welch, A., Bingham, S.., van Tol, A. see Hovingh, G.K. Day, N.E. & Wareham, N.J. Microalbuminuria and stroke in a Tonstad, S., Rosvold, E.O., Furu, K. & Skurtveit, S. Under- British population: the European Prospective Investigation treatment and overtreatment with statins: the Oslo Health into Cancer in Norfolk (EPIC-Norfolk) population study, 247 Study 2000-2001, 494 Tormos, C. see Giner, V. Tornvall, P. see Saleh, N. Zakopoulos, N. see Vemmos, K.N. Tracey, K.J. see Andersson, U.G. Zethelius, B. see Dunder, K. Tracey, K.J. see Wang, H Zocco, M.A. see Ojetti, \ Tressler, C.S. see Gleim, G.W. l'sivgoulis, G. see Vemmos, K.N. Valdivielso, P.> , Calandra, S., Duran, J.C., Garuti, R., Herrera, E. & Gonzalez, P. Coronary heart disease in a patient with cerebrotendinous xanthomatosis, 680 Vandenput, L. see Boonen, S. ( 2004 Blackwell Publishing Ltd Journal of Internal Medicine 255: 7 a ee Journal of Internal Medicine 2004; 255: 36-7 37 Keyword index x(1,3/1,4)-L-fucosyltransferase, 40 chronic renal failure, 115 fracture reduction, acute myocardial infarction, 57] clinical history, 469 fraud, 151 acute stroke, 257 clinical trial, 309, 427 FUT3 gene, 40 adipokines, 439 CLIP score, 399 adipose, 439 clopidogrel, 562 GADA, 384 adipose tissue, 448, 595 coarctation, 130 genistein, 602 adverse drug reaction, 653 coffee, 89, 645 glucose intolerance, 645 age. 266 cohort, 108, 579 goitre, 610 ageing, 52, 486 compliance, 96 GRETCH model, 399 albuminuria, 247 conflict of interest, 151 guidelines, 309, 494 alcoholic beverages. 280 confounding factors, 280 alendronate, 503 coronary angiography, 478 amoxicillin-clavulanate, 125 coronary heart disease, 680 health economics, 151 amyloid. 159 coronary syndrome, 469 heart rate variability, 13 amyloidosis, 159 cost-effectiveness, 562 heparin sulphates, 351 Anderson—Fabry disease, 629 Cox model, 521 hepatitis C virus, 399 angiogenesis, 538 C-peptide, 384 hepatocelluar carcinoma, 399 antibody response, 664 C-reactive protein, .72) higher H. pylori eradication rate, 125 antioxidants, 588 cross-sectional studies, 645 hip fracture, 108 antiphospholipid syndrome, 296 cyatiolk ine, ; a3s1 8, 234444 HMG, 351 aortic hypoplasia, 130 HMGB, 332 apolipoproteins, 188 daidzein, 602 HMGB1, 318, 320, 344 apoproteins, 273 data and safety monitoring, 151 HHooddggkkiinn’’ss dliysmeapsheo, ma2,8 9 664 apoptosis, 409 decision models, 562 hospital readmission, 653 aarrttherriitoisg,e nes3i2s0,, ddieavbeeltoesp,m en8t9,, 963,3 2 236, 384 hhuummaanns , her3p73e svirus 4, 289 aaaattturrhtiieaaorlli omsmfscitulbanerniridlotsltsyaii,tls il o,n ,4 019 , 674 188, 680 dddiiiaaabbgeenttoeesssi s,mm eell5ll7ii1tt uuss, t4y3pe9 2, 179 hhhyyypppeeerrrttlerinipsgiildoyan-e,cm eirai,5d 9,a e6m82i 3a6,, 6588 8 diet, 68, 373 hypotension, 486 DNA damage, 588 B-lactamase inhibitor, 125 doctor's practice patterns, 478 Bayesian methods, 521] dual energy X-ray absorptiometry [A-2A, 384 BCLC staging system, 399 (DEXA), 392 ICA, 384 biguanides, 1] yg IGF-I and IGFBP-1 levels, | biochemica rkers, 469 ECG, 469 inflammation, 318, 320, bbiirstph howsepihgohnta,t es, 503 echocardiography, 206 iinnffloirxmiamtaib,o n 40t9e chnology, 653 economics, 562 insulin, 82, 96, 645 bblloooodd gplruecsossuer,e , 962 36, 257. elderly, 96 insulin resistance, 74, 273, body composition, 392 electrocardiogram, 213, > >] insulin resistance syndrome, electrocardiography, 206 bone density, 1 embolism, 22 insulin secretion, 221 bone microarchitecture, 1 intent to treat, 529 emergency department, 579 bone mineral density, 392 intima—media thickness. 52 brachial artery, 379 eennddootthheelliiaall cfeulnl,c ti5o3n8, 379 intracerebral haemorrhage, 2 brain natriuretic peptide. 206 ischaemic heart disease, 367 3rugada syndrome, 137 enterolactone, 602 ischaemic stroke, 257 epidemiology, 373, 579, 645 exercise test, 478 ketoa‘ cids low pI rotein diet, : 115 cardiac variant, 629 cardiovascular, 229, 457 F-18-fluorodeoxyglucose, 419 cardiovascular disease, 13, 247, 4 Fabry disease, 629 lactate dehydrogenase isoenzyme, 512 494, 562 family history, 229, 494 lactic acidosis, 179 cardiovascular risk, 188 fat mass, 392 left bundle branch block, 571 carditis, 296 fetal growth retardation, 82 left ventricular systolic dysfunction, carotid atherosclerosis. 40 fever, 674 Lewis gene, 40 carrier females, 629 fever of unknown origin (FUO), 419 lipid-lowering therapy, 367 case series, 179 fibrates, 188 logrank, 521 cell migration, 351 fibril protein, 159 longitudinal, 266 cerebrotendinous xanthomatosis, 680 fibrinogen, 59 lymphocyte subsets, 512 cerebrovascular accident, 247 fibrinolysis, 448 cholestanol, 680 fibromuscular dysplasia, 130 maternal, 229 cholesterol, > 236. 367, 680 flow-mediated dilatation, 379 metabolic syndrome, 74 chromatin, 22?2 332 forensic diagnosis, 213 metastasis, 3322 2 chronic heart failure, 206 fracture, 108 metformin, 1 / 9 2004 Blackwell Publishing Ltd KEYWORD INDEX methodology, 427 prehospital, 469 soluble P-selectin, 59 microalbuminuria, 588 preterm birth, 82 splenectomy, 664 Minnesota code, 213 prevention, 22, 494, 615 statins, 188, 367, 494 mortality, 13, 68, 229, 257, primary hyperparathyroidism, 108 stem cells, 538 mortality prediction, 579 Procainamide, 137 stent implantation, 33 mRNA, 595 procedure time, 33 Sterol 27-hydroxylase, 680 multiple ROC analysis, 512 prognosis, 13, 469, 512 stroke, 22 myelodysplastic syndrome, 674 prospective study, 280 ST-segment monitoring, 571] myocardial infarction, 33, 221, 296. protein, 595 subcutaneous, 595 486, 637 proteinuria, 247 subgroups, 529 myocardial revascularization, 478 pylephlebitis, 419 sudden cardiac death, 213 surgery. 108 necrosis, 318, 344 Q/QS pattern, 221 surrogate outcomes, 529 nephropathy, 602 ORS complex, 206 surveys, 309 neurite outgrowth, 351 quality of care, 653 Sweden, 213. 562 nicotine, 379 symptoms, 629 nniocno-tLianincg erahciadn,s -c18e8l l histiocytosis, 289 RRAAGGEE, li3g5a1n d, 318 ssyysstteemmiicc almuypluosi deorsyist,h ema1t5o9 sus, 409 nucleosomes, 409 raloxifene, 503 nutritional status, 115 randomization, 521 therapy. 344 randomization bias, 151 thyroid volume, 610 obesity, 74, 439 randomized, 309 INF, 320 Okuda staging system, 399 registers, 367 treatment, 96 omental, 595 renal variant, 629 treatment outcome. +78 omeprazole, 125 resistin, 439 trial ethics, 151 oral anti-coagulants, 22 resource utilization, 653 triglyceride-rich lipoproteins, 273 orthostatic hypotension, 486 revaccination, 664 triglycerides, 74, 236 osteoporosis, 1, 615 rheological indices, 59 triple therapy, 125 overweight, 102 rheumatic fever, 296 troponin T, 33 oxidative stress, 588 rheumatoid arthritis, 409 type 1 diabetes, 602 risk factors, 68, 179, 229, 247, 457, type 1 diabetes mellitus, 39 ? type 2 diabetes mellitus, 64 = PAI-1, 448 588, 615, 637 Papua New Guinea, 3 —i™e72 pathogenesis, 344 $100, 351 ultrasonics, 52 pathophysiology, 512 sample size, 521 ultrasonography, 610 percutaneous coronary intervention, 33 SCN5SA, 137 ultrasound, 379 perilipin, 595 scoring system, 579 uric acid. 373 pharmacology, 615 secular trend, 457 urinary iodine, 610 pharmaco-vigilance, 65 >) selective oestrogen receptor modulators, physical exercise, 52 503 vaccination, 664 phyto-oestrogens, 602 sepsls, 318, 320 vascular endothelial growth factor, 538 plasma viscosity, 59 septic thrombophlebitis, 419 vasculitis, 674 platelet aggregation, 637 serum lipids, 82 vasculogenesis, 538 platelet glycoprotein GP IIb/IIIa complex, severe acute respiratory syndrome vectorcardiography, 571 637 (SARS), 512 ventricular fibrillation, 137 platelets, 637 shock, 320 viral DNA, 289 pneumococcal, 664 side effects, 125 polymorphism, 637 skeletal muscle, 11 weight gain, 266 poor prognosis, 221] skinfold thickness, von Willebrand factor, 59 population, 89, 610 smokeless tobacco, women, 13, 82, 89, 266 positron emission tomography, 419 smoking, 68, 102 women’s health, 615 postmenopausal, 615 smoking cessation, postmenopausal osteoporosis, 503 snuff, 379 post-prandial, 273 snus, 102 young, 213 postprandial lipaemia. 74 social class, 229, 280 young adults, 384 © 2004 Blackwell Science Ltd Journal of Internal Medicine 255: 7